Why China Is Reshaping Global Oncology Trials

Beyond policy and projections, real-world trial execution provides the clearest insight into a clinical environment.

Recent regulatory reforms, strong patient access, and improving trial quality in China are altering long-held assumptions about where trials can be conducted efficiently and at scale. Insights shared at ESMO 2025 offer a data-driven view of how these changes are playing out in practice

This executive summary brings together regulatory context, enrollment data, and real-world trial experience to examine what China’s evolving clinical environment means for global oncology development.

Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.

By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).